Faculty Profiles - TAKAHASHI, Yoshiyuki

Papers - TAKAHASHI, Yoshiyuki

Division display 161 - 180 of about 517 ／ All the affair displays >>

Genetic Study of Fanconi Anemia in Infancy Revealed FANCI Mutations and Defective ALDH2 Variant: A Case Report

Urata, T; Imamura, T; Osone, S; Muramatsu, H; Takahashi, Y; Hosoi, H

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY Vol. 44 ( 2 ) page： E438 - E441 2022.3

Short Report Nosocomial infection with rotavirus vaccine strain in paediatric patients with immunodeficiency

Miura, H; Taniguchi, K; Narita, K; Kawamura, Y; Kozawa, K; Muramatsu, H; Takahashi, Y; Ihira, M; Yoshikawa, T

JOURNAL OF HOSPITAL INFECTION Vol. 121 page： 9 - 13 2022.3

Prospective validation of the provisional entity of refractory cytopenia of childhood, proposed by the World Health Organization Open Access

Hama, A; Hasegawa, D; Manabe, A; Nozawa, K; Narita, A; Muramatsu, H; Kosaka, Y; Kobayashi, M; Koh, K; Takahashi, Y; Watanabe, K; Ohara, A; Ito, M; Kojima, S

BRITISH JOURNAL OF HAEMATOLOGY Vol. 196 ( 4 ) page： 1031 - 1039 2022.2

Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia

Tsuzuki, S; Yasuda, T; Kawazu, M; Ueno, T; Karnan, S; Ota, A; Sanada, M; Nagai, H; Tomita, A; Takahashi, Y; Miyazaki, Y; Matsumura, I; Kiyoi, H; Hosokawa, Y; Mano, H; Hayakawa, F

CANCER SCIENCE Vol. 113 page： 1236 - 1236 2022.2

Dyserythropoietic anaemia with an intronic GATA1 splicing mutation in patients suspected to have Diamond-Blackfan anaemia. International journal Open Access

Akie Kobayashi, Ryusei Ohtaka, Tsutomu Toki, Junichi Hara, Hideki Muramatsu, Rika Kanezaki, Yuka Takahashi, Tomohiko Sato, Takuya Kamio, Ko Kudo, Shinya Sasaki, Taro Yoshida, Taiju Utsugisawa, Hitoshi Kanno, Kenichi Yoshida, Yasuhito Nannya, Yoshiyuki Takahashi, Seiji Kojima, Satoru Miyano, Seishi Ogawa, Kiminori Terui, Etsuro Ito

EJHaem Vol. 3 ( 1 ) page： 163 - 167 2022.2

Language：English Publishing type：Research paper (scientific journal)

Diamond-Blackfan anaemia (DBA) shares clinical features with two recently reported sporadic cases of dyserythropoietic anaemia with a cryptic GATA1 splicing mutation (c.871-24 C>T). We hypothesized that some patients clinically diagnosed with DBA but whose causative genes were unknown may carry the intronic GATA1 mutation. Here, we examined 79 patients in our DBA cohort, who had no detectable causative genes. The intronic GATA1 mutation was identified in two male patients sharing the same pedigree that included multiple cases with anaemia. Cosegregation of this mutation and disease in multiple family members provide evidence to support the pathogenicity of the intronic GATA1 mutation.

DOI： 10.1002/jha2.374

Open Access

Web of Science

PubMed

胎児発育不全モデルラットの脳脊髄液中タンパク質の網羅的解析脳発達異常の病態解明に向けて

小野田淳人, 北瀬悠磨, 辻雅弘, 上田一仁, 高橋義行, 早川昌弘, 佐藤義朗

日本小児科学会雑誌 Vol. 126 ( 2 ) page： 414 - 414 2022.2

投与経路に着目したMultilineage-differentiating stress enduring cell(Muse細胞)を用いた新生児慢性肺疾患の新規治療法開発

三浦良介, 佐藤義朗, 小野田淳人, 藤本健志, 後藤良子, 高本幸奈, 神澤孝洋, 鈴木紗記子, 上田一仁, 徐悦, 橋本佑樹, 落合加奈代, 谷口顕信, 田中龍一, 伊藤美春, 齊藤明子, 村松友佳子, 清水忍, 高橋義行, 早川昌弘

日本小児科学会雑誌 Vol. 126 ( 2 ) page： 250 - 250 2022.2

TREC測定による新生児マススクリーニングにより診断され同種臍帯血移植を行ったX連鎖重症複合免疫不全症

山下大紀, 村松秀城, 今屋雅之, 山森彩子, 若松学, 片岡伸介, 濱田太立, 谷口理恵子, 川島希, 西川英里, 成田敦, 奥野友介, 西尾信博, 小島大英, 中島葉子, 柘植郁哉, 中村冨美子, 酒井好美, 伊藤哲哉, 高橋義行

日本小児科学会雑誌 Vol. 126 ( 2 ) page： 281 - 281 2022.2

TREC測定による新生児マススクリーニングにより診断され同種臍帯血移植を行ったX連鎖重症複合免疫不全症

日本小児科学会雑誌 Vol. 126 ( 2 ) page： 281 - 281 2022.2

New mimic of relapse or regional lymph node metastasis in a cancer survivor: a case of mRNA COVID-19 vaccine-induced lymphadenitis with high FDG uptake Open Access

Tsumura, Y; Asakura, K; Takahashi, I; Akaihata, M; Takahashi, Y; Ishida, Y

IMMUNOLOGICAL MEDICINE Vol. 45 ( 1 ) page： 45 - 47 2022.1

Dorsal myelopathy after nelarabine and intrathecal methotrexate therapy

Sawamura, F; Natsume, J; Nakata, T; Muramatsu, H; Takahashi, Y

PEDIATRICS INTERNATIONAL Vol. 64 ( 1 ) page： e15334 2022.1

Conception by assisted reproductive technology in infants with critical congenital heart disease in Japan.

Morimoto Y, Go K, Yamamoto H, Fukasawa Y, Nakai M, Morihana E, Yasuda K, Nishikawa H, Ohashi N, Takahashi Y, Kato T

Reproductive biomedicine online Vol. 44 ( 1 ) page： 163 - 170 2022.1

Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation. International journal Open Access

Ryo Maemura, Manabu Wakamatsu, Kana Matsumoto, Hirotoshi Sakaguchi, Nao Yoshida, Asahito Hama, Taro Yoshida, Shunsuke Miwata, Hironobu Kitazawa, Kotaro Narita, Shinsuke Kataoka, Daisuke Ichikawa, Motoharu Hamada, Rieko Taniguchi, Kyogo Suzuki, Nozomu Kawashima, Eri Nishikawa, Atsushi Narita, Yusuke Okuno, Nobuhiro Nishio, Koji Kato, Seiji Kojima, Kunihiko Morita, Hideki Muramatsu, Yoshiyuki Takahashi

Cell transplantation Vol. 31 page： 9636897221143364 - 9636897221143364 2022

Language：English Publishing type：Research paper (scientific journal)

Melphalan is widely used for hematopoietic stem cell transplantation (HSCT) conditioning. However, the relationship between its pharmacokinetic (PK) and transplantation outcomes in children has not been thoroughly investigated. We prospectively analyzed the relationship between melphalan area under the curve (AUC) and transplantation outcome and examined the development of a predictive model for melphalan clearance in children. This study included 43 children aged 0 to 19 years who underwent HSCT following a melphalan-based conditioning regimen from 2017 to 2021. In univariable analysis, high-melphalan AUC resulted in a significantly lower cumulative incidence of acute graft-versus-host disease and a higher cumulative incidence of thrombotic microangiopathy, although no significant difference was observed in survival. Regression analysis of a randomly selected derivation cohort (n = 21) revealed the following covariate PK model: predicted melphalan clearance (mL/min) = 6.47 × 24-h urinary creatinine excretion rate (CER, g/day) × 24-h creatinine clearance rate (CCR, mL/min) + 92.8. In the validation cohort (n = 22), the measured melphalan clearance values were significantly correlated with those calculated based on the prediction equation (R2 = 0.663). These results indicate that melphalan exposure may be optimized by adjusting the melphalan dose according to CER and CCR.

DOI： 10.1177/09636897221143364

Web of Science

PubMed

Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. International journal Open Access

Hironobu Kitazawa, Yusuke Okuno, Hideki Muramatsu, Kosuke Aoki, Norihiro Murakami, Manabu Wakamatsu, Kyogo Suzuki, Kotaro Narita, Shinsuke Kataoka, Daisuke Ichikawa, Motoharu Hamada, Rieko Taniguchi, Nozomu Kawashima, Eri Nishikawa, Atsushi Narita, Nobuhiro Nishio, Asahito Hama, Mignon L Loh, Elliot Stieglitz, Seiji Kojima, Yoshiyuki Takahashi

Blood advances Vol. 5 ( 24 ) page： 5507 - 5518 2021.12

Language：English Publishing type：Research paper (scientific journal)

Juvenile myelomonocytic leukemia (JMML) is a rare myelodysplastic/myeloproliferative neoplasm that develops during infancy and early childhood. The array-based international consensus definition of DNA methylation has recently classified patients with JMML into the following 3 groups: high (HM), intermediate (IM), and low methylation (LM). To develop a simple and robust methylation clinical test, 137 patients with JMML were analyzed using the Digital Restriction Enzyme Analysis of Methylation (DREAM), which is a next-generation sequencing-based methylation analysis. Unsupervised consensus clustering of the discovery cohort (n = 99) using DREAM data identified HM (HM_DREAM; n = 35) and LM subgroups (LM_DREAM; n = 64). Of the 98 cases that could be compared with the international consensus classification, 90 HM (n = 30) and LM (n = 60) cases had 100% concordance with DREAM clustering results. Of the remaining 8 cases comprising the IM group, 4 were classified as belonging to the HM_DREAM group and 4 to the LM_DREAM group. A machine-learning classifier was successfully constructed using a support vector machine (SVM), which divided the validation cohort (n = 38) into HM (HM_SVM, n = 18) and LM (LM_SVM; n = 20) groups. Patients with the HM_SVM profile had a significantly poorer 5-year overall survival rate than those with the LM_SVM profile. In conclusion, we developed a robust methylation test using DREAM for patients with JMML. This simple and straightforward test can be easily incorporated into diagnosis to generate a methylation classification for patients so they can receive risk-adapted treatment in the context of future clinical trials.

DOI： 10.1182/bloodadvances.2021005080

Web of Science

PubMed

Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation

Yokoyama, H; Hirayama, M; Takahashi, Y; Uchida, N; Tanaka, M; Onizuka, M; Ozawa, Y; Onai, D; Katsuoka, Y; Wake, A; Sawa, M; Kobayashi, H; Maruyama, Y; Ozeki, K; Kimura, T; Kanda, J; Fukuda, T; Atsuta, Y; Terakura, S; Morishima, S

BONE MARROW TRANSPLANTATION Vol. 56 ( 12 ) page： 3059 - 3067 2021.12

Effectiveness of lacosamide in children and young adults previously treated with other sodium channel blockers

Suzuki, T; Natsume, J; Kumai, S; Maki, Y; Yamamoto, H; Numoto, S; Narahara, S; Kubota, T; Tsuji, T; Kato, T; Yamada, K; Maruyama, K; Okumura, A; Takahashi, Y; Kidokoro, H

EPILEPSY & BEHAVIOR Vol. 125 page： 108397 2021.12

Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome. International journal

Shohei Yamamoto, Motohiro Kato, Kenichiro Watanabe, Sae Ishimaru, Daisuke Hasegawa, Maiko Noguchi, Asahito Hama, Maho Sato, Takashi Koike, Fuminori Iwasaki, Hiroshi Yagasaki, Yoshiyuki Takahashi, Yoshiyuki Kosaka, Yoshiko Hashii, Akira Morimoto, Yoshiko Atsuta, Daiichiro Hasegawa, Nao Yoshida

Bone marrow transplantation Vol. 56 ( 12 ) page： 3016 - 3023 2021.12

Language：English Publishing type：Research paper (scientific journal)

Cytogenetic abnormalities are a major risk factor for relapse after hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS). We aimed to evaluate the value of the five-group cytogenetic classification according to the revised International Prognostic Scoring System (R-IPSS) for predicting the outcome after HSCT in pediatric patients with MDS. We retrospectively analyzed the Japanese registration data of 242 pediatric patients with MDS. According to the R-IPSS classification, 112 (45.5%) patients had good, 55 (22.7%) had intermediate, 64 (26.4%) had poor, and 11 (4.6%) had very poor cytogenetics. The 5-year overall survival (5yOS) was 72%, 69%, 59%, and 30% in the good, intermediate, poor, and very poor cytogenetic subgroups (p = 0.026), respectively. The very good, good, and intermediate subgroups were grouped into a "standard" subgroup and reclassified into three subgroups (standard, poor, and very poor). Patients with very poor risk had worse 5yOS (hazard ratio 2.17, 95% confidence interval (CI) 1.02-4.61; p = 0.04) and a much higher 5yCIR (hazard ratio 2.52, 95% CI 1.05-6.04; p = 0.04) than those of patients in the standard group in the multivariate analysis, indicating that very poor risk cytogenetic characteristics independently predicted worse outcome after HSCT in pediatric patients with MDS.

DOI： 10.1038/s41409-021-01446-z

Web of Science

PubMed

[Recommendations (Proposal) for promoting research for overcoming neurological diseases 2020].

Mochizuki H, Aoki M, Ikenaka K, Inoue H, Iwatsubo T, Ugawa Y, Okazawa H, Ono K, Onodera O, Kitagawa K, Saito Y, Shimohata T, Takahashi R, Toda T, Nakahara J, Matsumoto R, Mizusawa H, Mitsui J, Murayama S, Katsuno M, Future Vision Committee of Japanese Society of Neurology, Aoki Y, Ishiura H, Izumi Y, Koike H, Shimada H, Takahashi Y, Tokuda T, Nakajima H, Hatano T, Misawa S, Watanabe H

Rinsho shinkeigaku = Clinical neurology Vol. 61 ( 11 ) page： 709 - 721 2021.11

A Phase I Study of CD19 Chimeric Antigen Receptor-T Cells Generated By the PiggyBac Transposon Vector for Acute Lymphoblastic Leukemia Open Access

Nishio, N; Hanajiri, R; Ishikawa, Y; Murata, M; Taniguchi, R; Hamada, M; Nishikawa, E; Kawashima, N; Narita, A; Muramatsu, H; Takahashi, Y

BLOOD Vol. 138 page： 3831 - + 2021.11

Clinical Features of Immature Leukemias in Children

Sajiki, D; Yoshida, N; Muramatsu, H; Sakaguchi, K; Maeda, N; Yokoyama, N; Miyajima, Y; Tanaka, M; Takahashi, Y; Hama, A

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

　 PREV - NEXT 　

<TAKAHASHI, Yoshiyuki>

Papers - TAKAHASHI, Yoshiyuki